title: A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons.
abstract: Chemical agents able to interfere with DNA topoisomerases are widespread in nature, and some of them have outstanding therapeutic efficacy in human cancer and infectious diseases. DNA topoisomerases are essential enzymes that govern DNA topology during fundamental nuclear metabolic processes. Topoisomerase-interfering compounds can be divided into two general categories based on the mechanism of drug action: poisons and catalytic inhibitors. In past years, investigations of the DNA sequence selectivity of topoisomerase II poisons have identified structural and molecular determinants of drug activity, and indicated that the drug receptor is likely to be at the protein-DNA interface. Moreover, the available results indicate that the biologically relevant DNA-binding activity of topoisomerase poisons is basically protein-mediated and this is discussed in this issue by Giovanni Capranico and colleagues. This suggests that topoisomerase poisons may represent a useful paradigm for small compounds able to bind to protein-DNA interfaces in a site-selective manner, thus increasing the affinity of DNA-binding proteins for specific genomic sites.
authors.affiliation: Division of Experimental Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Capranico
authors.forename: M
authors.initials: M
authors.lastname: Binaschi
authors.forename: M E
authors.initials: ME
authors.lastname: Borgnetto
authors.forename: F
authors.initials: F
authors.lastname: Zunino
authors.forename: M
authors.initials: M
authors.lastname: Palumbo
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D001483:Base Sequence / Q000187:drug effects*; D004791:Enzyme Inhibitors / Q000633:toxicity*; D006801:Humans; D059005:Topoisomerase II Inhibitors
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D059005:Topoisomerase II Inhibitors